Table 1.
Signatera blood draw frequency based on immunotherapy treatment regimen (Prospective Signatera arm)
| Immunotherapy treatment regimen |
Immunotherapy treatment dose | Treatment frequency (every # weeks) |
Signatera blood draw Frequency*† (every # weeks) |
| Atezolizumab (Tecentriq) | 840 mg | 2 | 8 |
| Atezolizumab (Tecentriq) | 1200 mg | 3 | 6 |
| Atezolizumab (Tecentriq) | 1680 mg | 4 | 8 |
| Avelumab (Bavencio) | 800 mg | 2 | 8 |
| Cemiplimab (Libtayo) | 350 mg | 3 | 6 |
| Durvalumab (Imfinzi) | 10 mg/kg | 2 | 8 |
| Durvalumab (Imfinzi) | 1500 mg | 4 | 8 |
| Durvalumab (Imfinzi) | 1500 mg | 3 | 6 |
| Ipilimumab (Yervoy) | 3 mg/kg | 3 | 6 |
| Nivolumab (Opdivo) | 240 mg | 2 | 8 |
| Nivolumab (Opdivo) | 480 mg | 4 | 8 |
| Nivolumab (Opdivo) and ipilimumab (Yervoy) | 1 mg/kg 3 mg/kg |
3 3 |
6 |
| Nivolumab (Opdivo) and ipilimumab (Yervoy) | 360 mg 1 mg/kg |
3 6 |
6 |
| Nivolumab (Opdivo) and ipilimumab (Yervoy) | 3 mg/kg 1 mg/kg |
3 3 |
6 |
| Nivolumab (Opdivo) and ipilimumab (Yervoy) | 3 mg/kg 1 mg/kg |
2 6 |
8 |
| Pembrolizumab (Keytruda) | 200 mg | 3 | 6 |
| Pembrolizumab (Keytruda) | 400 mg | 6 | 6 |
*Signatera blood draw should coincide with every other treatment cycle.
†Additional optional Signatera blood draws are recommended on weeks 2–4 of immunotherapy, and 4–6 weeks after the end of treatment or disease progression.